Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | HTR2B | P41595 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.75 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.75 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CTSD | P07339 | 2/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7987508 | 1.00 | CYP3A4 (0.75) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL7977464 | 0.91 | CYP3A4 (0.62) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL2059564 | 0.91 | CYP3A4 (0.62) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL7988988 | 0.91 | CYP3A4 (0.61) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL2059543 | 0.90 | CYP3A4 (0.61) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL9951913 | 0.90 | ABCC3 (0.61) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL7994627 | 0.90 | CYP3A4 (0.60) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL7988693 | 0.88 | CYP3A4 (0.58) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL7987596 | 0.88 | CYP3A4 (0.57) | CYP3A4ABCC3ABCC4ABCB11PGR | |
| SCHEMBL7994649 | 0.86 | CYP3A4 (0.56) | CYP3A4ABCC3ABCC4ABCB11PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796451-B2 | Crystalline pharmaceutical | ABBVIE INC. (US) | 2014-08-05 | — | — | US | claimed |
| US-20070027172-A1 | Crystalline pharmaceutical | ABBOTT LABORATORIES | 2007-02-01 | — | — | US | claimed |
| US-20140303369-A1 | Crystalline Pharmaceutical | ABBVIE INC (US) | 2014-10-09 | — | — | US | disclosed |
| US-8796451-B2 | Crystalline pharmaceutical | ABBVIE INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20110281900-A1 | Crystalline Pharmaceutical | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| US-8058433-B2 | Crystalline pharmaceutical | ABBOTT LABORATORIES (US) | 2011-11-15 | — | — | US | disclosed |
| US-20070027172-A1 | Crystalline pharmaceutical | ABBOTT LABORATORIES | 2007-02-01 | — | — | US | disclosed |
| US-20050124810-A1 | Purity; hydrate forms | DICKMAN DANIEL A (US) | 2005-06-09 | — | — | US | disclosed |
| US-6608198-B2 | Hydrated forms of lopinavir; HIV protease inhibitor | ABBOTT LABORATORIES | 2003-08-19 | — | — | US | disclosed |
| EP-1268442-A2 | CRYSTALLINE PHARMACEUTICAL | Abbott Laboratories (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20010051721-A1 | Hydrated forms of lopinavir; HIV protease inhibitor | ABBVIE INC. | 2001-12-13 | — | — | US | disclosed |
| WO-2001074787-A2 | CRYSTALLINE PHARMACEUTICAL | ABBOTT LABORATORIES (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124810-A1 | Purity; hydrate forms | SAMHD1, ACE, CYP3A4 | CYP3A4 3/4885ABCC3 173/4885ABCC4 127/4885 |
| US-20010051721-A1 | Hydrated forms of lopinavir; HIV protease inhibitor | SERPINB1, HPN, ACE | CYP3A4 59/4885ABCC3 260/4885ABCC4 331/4885 |
| US-20140303369-A1 | Crystalline Pharmaceutical | PYGL, ACE, HDLBP | CYP3A4 21/4885ABCC3 113/4885ABCC4 133/4885 |
| US-20110281900-A1 | Crystalline Pharmaceutical | PYGL, ACE, HDLBP | CYP3A4 21/4885ABCC3 112/4885ABCC4 133/4885 |
| US-20070027172-A1 | Crystalline pharmaceutical | PYGL, ACE, HDLBP | CYP3A4 21/4885ABCC3 112/4885ABCC4 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.